Research groups
Parvinder Aley
Director of Operations (OVG)
Parv joined the Oxford Vaccine Group in May 2016. She has a PhD in Cellular Physiology from the University of Leeds. Subsequently she moved to Oxford where she has worked at the University for the past 10 years, initially as a researcher and more recently as a Contracts Specialist. As Operational Manager, she is responsible for the strategic management of the group with the aim to facilitate research on the development and implementation of vaccines.
Recent publications
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
The ‘Be on the TEAM’ Study (Teenagers Against Meningitis): Protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents
Journal article
MAIDEN MCJ. et al, (2020), BMJ Open
-
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger in muscarinic receptor-induced contraction of guinea pig trachea.
Journal article
Aley PK. et al, (2013), J Biol Chem, 288, 10986 - 10993